Septerna logo

Septerna

SEPN | NASDAQ
Chart Builder DCF Calculator
$41.67
-$0.93 (-2.18%)
At close: Nov 16, 2026, 4:00 PM ET
$41.67
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.18%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
39.5
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #544/1021 (Top 53%)

Key Statistics

Market Data

Market Cap $1.98B
1D Range
40.80 42.95
52W Range
21.64 52.34

Valuation (TTM)

PE -32.30
PB 4.63
EV/EBITDA -29.43

Valuation (NTM)

Forward PE N/A
Forward PEG -1.03
Price Target $49.00
Loading financial charts...

Profile

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflamm...

Sector Healthcare
Industry Biotechnology
Employees 123
IPO Date Oct 25, 2024
Fiscal Year January - December

Latest News

Septerna: The SEP-479 Readout Could Unlock Further Upside

5 days ago · seekingalpha.com

Septerna: The SEP-479 Readout Could Unlock Further Upside
Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates

7 days ago · zacks.com

Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

13 days ago · globenewswire.com

Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
Septerna to Participate in Upcoming Investor Conferences

14 days ago · globenewswire.com

Septerna to Participate in Upcoming Investor Conferences
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

3 months ago · globenewswire.com

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

3 months ago · zacks.com

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

5 months ago · fool.com

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

6 months ago · zacks.com

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

6 months ago · globenewswire.com

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Septerna to Present at Bank of America Securities Health Care Conference

7 months ago · globenewswire.com

Septerna to Present at Bank of America Securities Health Care Conference

Earnings

Latest Earnings
Nov 9, 2026
EPS
-$0.57
Miss -37.35%
REV
$18.88M
Miss -9.14%
Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$49.00
Upside
+17.59%
Buy (9)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.